Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "Press release and presentation on the financials and operational performance of the Company for the Quarter and Financial Year ended March 31, 2026".
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Ingrevia reported strong Q4 FY26 results with revenue of Rs 1,179 crore (+12% YoY) and EBITDA of Rs 172 crore (+11% YoY, +26% QoQ), marking the highest quarterly revenue in 14 quarters. FY26 full-year revenue was Rs 4,388 crore (+5%) and EBITDA was Rs 607 crore (+9%). PAT grew 17% YoY to Rs 86 crore in Q4 and 11% for FY26 to Rs 278 crore. The board recommended a final dividend of Rs 2.50 per share, taking the total FY26 dividend to Rs 5 per share (500%). Specialty Chemicals led with 27% EBITDA margins and 21% EBITDA growth for FY26. Net debt reduced 11% YoY to Rs 587 crore, with Net Debt/EBITDA improving to 0.99x. The company also completed acquisition of Remidex Pharma to expand into human nutrition premixes and commenced dispatch from its newly constructed agro CDMO facility.
Strong operational execution with margin expansion and a robust order pipeline of Rs 3,400+ crore provides good visibility. The improving portfolio mix toward higher-margin Specialty Chemicals and Nutrition, combined with sequential growth guidance for Q1 FY27, is positive for the stock.